Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Rhea-AI Summary
Axogen (Nasdaq: AXGN) will release fourth quarter and full year 2025 financial results on February 24, 2026. Management will host an investor conference call and webcast at 8:00 a.m. ET following the release.
Investors can join by phone at the provided toll-free or direct dial numbers, and a live webcast, archived replay, and presentation slides will be available on the company Investors page at www.axogeninc.com.
Positive
- None.
Negative
- None.
News Market Reaction – AXGN
In the Feb 10 session, AXGN gained 1.71%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | Equity offering priced | Negative | +3.6% | Priced upsized public offering of 4,000,000 shares at $31.00 per share. |
| Jan 21 | Equity offering proposed | Negative | +3.6% | Announced proposed $85.0M common stock offering with 30-day underwriter option. |
| Jan 12 | Preliminary 2025 results | Positive | -5.8% | Preliminary Q4 and full-year 2025 revenue growth above 20% with strong margins. |
| Dec 17 | Conference participation | Positive | +7.0% | Announced presentation at the J.P. Morgan 2026 Healthcare Conference for investors. |
| Dec 03 | FDA Avance approval | Positive | +2.3% | FDA approved Avance BLA for multiple peripheral nerve indications, including accelerated approval. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often produced strong but mixed reactions, with both positive fundamentals and dilutive offerings sometimes moving opposite to intuitive expectations.
Over the past few months, Axogen reported several key developments. On December 3, 2025, the company received FDA approval for its Avance biologic, followed by participation in the J.P. Morgan 2026 Healthcare Conference. On January 12, 2026, Axogen released strong preliminary 2025 revenue of about $225.2 million with gross margin above 74%. Shortly after, the company launched and priced an upsized equity offering of 4,000,000 shares at $31.00, aimed in part at repaying its Oberland credit facility. Today’s earnings-date announcement fits into this ongoing disclosure cadence around 2025 performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available on the Investors page of the company's website at www.axogeninc.com.
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
